Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare and devastating diseases through the discovery, development and commercialization of life-changing medicines. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Alexion Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 Q1 21
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Alexion Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 Q1 21 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Alexion Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 Q1 21 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Alexion Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 Q1 21 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Alexion Pharmaceuticals assets
Alexion Pharmaceuticals cash flows
Alexion Pharmaceuticals news
21.07.2021
AstraZeneca completed its merger with Alexion Pharmaceuticals. Alexion was valued at $39 billion. AstraZeneca shareholders received $60 and 2.1243 ADRs for each of their shares. They now own 15% of the combined company.
16.07.2021
Alexion Pharmaceuticals is excluded from the S&P 500 Index as of July 21, 2021. Its place in the index will be taken by Moderna.
08.06.2021
FDA has expanded the use of the drug ULTOMIRIS, developed by Alexion Pharmaceuticals. It can now be used to treat children and adolescents under the age of 18 with paroxysmal nocturnal hemoglobinuria.
30.04.2021
Alexion Pharmaceuticals' GAAP net income for 3 months 2021 was $489.2 million, down 12.3% from $557.6 million in the previous year. Revenue increased 43% to $1.637 billion compared to $1.145 billion a year earlier.
General information
Company nameAlexion Pharmaceuticals
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address121 SEAPORT BOULEVARD BOSTON MA 02210 4752302596
Mailing address121 SEAPORT BOULEVARD BOSTON MA 02210
Websitewww.alexion.com
Information disclosurewww.sec.gov